H
ealth care administrators and policymakers are increasingly turning to nurse-led disease management to lessen the economic and health burden of chronic diseases, such as heart failure. Meta-analyses of randomized, controlled trials (RCTs) suggest that nurse management can be effective at reducing rehospitalization and sometimes at improving functioning (1) . To our knowledge, however, no previous RCT has included a cost-effectiveness analysis sufficient to inform policymakers as to whether nurse management improves quality of life for patients with heart failure at a reasonable cost to society. Studies have not followed recommended cost-effectiveness guidelines or thoroughly calculated intervention costs (2) . Establishing the cost-effectiveness of nurse management for heart failure may be especially important in minority communities, which have disproportionate rates of hospitalization for heart failure (3) and shortfalls in the use of proven effective therapies (4) and in patients' understanding of heart failure (5) .
We aimed to estimate the cost-effectiveness of a nurseled disease management intervention that was conducted alongside a randomized, controlled effectiveness trial. The trial, conducted in Harlem, New York, from 1999 to 2003, found that patients in the nurse-managed group maintained better physical functioning, as measured by the Short Form-12 (SF-12) physical component score, and had statistically significantly fewer hospitalizations than did patients in the control group (6) .
METHODS
For the RCT, we recruited patients from outpatient clinics at the 4 hospitals serving East and Central Harlem in New York City. We randomly assigned 406 patients to usual care (203 patients) or a nurse-led program (203 patients) in which patients had 1 in-person visit with a trained nurse and periodic follow-up telephone calls over 12 months (6) . The nurses stressed adherence to a low-salt diet and to medications and worked with the patient's physician to optimize heart failure medications according to published guidelines. Primary outcomes were total hospi-talizations and physical functioning as measured by the SF-12 physical component score. Trained surveyors who were blinded to treatment assignment called patients in both groups every 3 months for 18 months to administer the SF-12 and collect information on health care utilization, amount of informal care received, and patients' estimates of their time engaged in receiving health care over the past 3 months.
We measured cost-effectiveness by using the incremental cost-effectiveness ratio (ICER), which is the difference in average costs between the nurse-managed and usual care groups (Cost N Ϫ Cost UC ) divided by the difference in mean quality-adjusted life-years (QALYs) (QALY N Ϫ QALY UC ):
ICER ϭ (Cost N Ϫ Cost UC )/(QALY N Ϫ QALY UC )
QALYs
We estimated QALYs for the 12-month intervention by translating the SF-12 physical and mental component scores into Health Utility Index Mark 3 (HUI3) and EuroQol-5D (EQ-5D) quality-of-life scores by using methods described by Franks and colleagues (7) . We chose these translations over other published methods (8 -10) because they were validated in African-American patients, and most of the patients in our trial were African American or Hispanic. Patients who died were assigned a quality-of-life score of 0 in subsequent periods. We calculated QALYs by connecting the 5 quality-of-life scores for each patient (baseline and quarterly through 12 months) by using straight lines and calculating the area of the resulting 4
Context
Although evidence indicates that nurse-led care management improves clinical outcomes for patients with heart failure, evidence on the economic benefits of these programs is lacking.
Contribution
Using data on costs from a randomized trial of 12 months of care management versus usual care for socioeconomically disadvantaged patients with heart failure, the investigators estimated that the cost-effectiveness of case management is less than $20 000/QALY.
Caution
The results might not apply to patients in less socioeconomically disadvantaged settings. trapezoids. We estimated adjusted differences in QALYs by the coefficient on treatment from a linear regression of each patient's QALY on his or her quality-of-life score at baseline and treatment assignment (11).
-The Editors

Societal Costs
We followed guidelines for cost-effectiveness analysis (2) to estimate costs from a societal perspective and included intervention, medical, and nonmedical costs (Appendix Table, available at www.annals.org). Intervention costs included all intervention materials (for example, scales), telephone service for 2 patients who did not have it, patients' transportation costs to the initial nurse meeting, nurses' salaries and fringe benefits, physician time overseeing the nurse activities, and costs for office space and equipment used by the nurses.
We derived medical costs for inpatient, outpatient, and emergency department use from administrative records from the 4 hospitals that participated in the trial.
For inpatient costs, we converted billed charges to costs by using the cost-to-charge ratio for each hospital (2, 12) and converted the costs to 2001 U.S. dollars by using the Producer Price Index for general and surgical hospitals (13) . For outpatient and emergency department claims, we applied the 2001 Medicare fee schedule for the New York City region (14) to billed procedure codes. For medication costs, we obtained medications prescribed from patients' charts and prices for those medications from the average prices paid by Medicaid (15) .
We used quarterly patient surveys to collect information on inpatient and outpatient utilization at nonparticipating institutions (to supplement administrative records from participating hospitals) and information on nonmedical costs, which included nursing home stays; patient transportation and time costs associated with medical encounters; and costs of informal care or assistance with household chores provided by friends, family members, or paid housekeepers. Costs are reported in 2001 U.S. dollars.
Because of skewed cost data and a high percentage of patients with zero costs for many cost categories, we evaluated the statistical significance of the difference in costs between nurse-managed and usual care groups by using 2-part gamma models (16) . In the first part, we estimated the probability of costs being greater than 0 by logistic regression, with treatment assignment; age; sex; race (nonHispanic black, non-Hispanic white, or other non-Hispanic); Hispanic ethnicity; recruitment site; education; preference for Spanish interview; New York Heart Association (NYHA) heart failure class; and indicators for diabetes, chronic pulmonary disease, and ischemic heart disease as explanatory variables. In the second part, for patients with costs greater than zero, we modeled costs as a function of the same explanatory variables by using generalized linear models with a gamma distribution and a logarithmic link function. For nursing home costs, which had a very small probability of being greater than 0, we calculated unadjusted differences in mean costs and bootstrapped SEs by using 500 replicates stratified by treatment.
We replaced missing observations for SF-12 scores and self-reported utilization with 10 imputed values found by using imputation by chained equations (17) as implemented by the ICE command in Stata, version 10.0 (StataCorp, College Station, TX) (18) . The previously listed explanatory variables at baseline and administrative data for hospitalizations and outpatient visits at baseline and quarterly follow-up were regressors in these equations. We estimated the 2-part models described previously on each imputed data set and combined the results by using Rubin's rules (19) .
Uncertainty in the ICER
We created 500 bootstrapped replicates (50 from each of the 10 imputations) and plotted the corresponding costeffectiveness acceptability curves (20) . We calculated approximate empirical CIs for the ICER by using the boot- strap percentile method (21) . To explore whether nurse management is more likely to be cost-effective for patients with varying heart failure severity, we computed separate acceptability curves according to baseline NYHA class.
Sensitivity Analysis
We estimated costs on the basis of national prices for all cost items. We used the national 2001 Medicare fee schedule to calculate costs for outpatient and emergency department use (14) , deflated costs for hospitalizations and self-reported medical use by the ratio of the United States to New York metropolitan area Consumer Price Index for medical care, and deflated nonmedical costs by the ratio of the United States to New York metropolitan area Consumer Price Index for urban dwellers (22) .
To characterize the cost implications from the payer's perspective, we also calculated costs to the Medicare program on the basis of categories and proportions of societal costs that Medicare typically covers. These included intervention costs but excluded costs for nursing home stays, patient time, telephone consultations, nonphysician office visits, and informal care. We decreased payer costs by the deductible and copayment rates for Medicare beneficiaries in 2001. We included drug costs because Medicare and most insurers now cover medications. We assumed the deductible and copayment rate of the 2006 Medicare prescription drug plan, but no coverage gap.
We investigated the influence of imputing missing survey data on the results by reporting the ICER for the observed data only (available data analysis) for patients who responded to every quarterly telephone survey until death or 12 months (complete case analysis) and for a data set in which a patient's missing observations were replaced with the mean value of that patient's observed responses (patient-specific imputation).
We conducted all analyses in Stata, version 10 (18). The study was approved by institutional review boards at each participating institution.
Role of the Funding Source
Funding was provided by the Agency for Healthcare Research and Quality. The funding source had no role in the design, conduct, or analysis of the study or in the decision to submit the manuscript for publication.
RESULTS
The sample of 203 usual care and 203 nurse-managed patients consisted mostly of black and Hispanic patients of lower socioeconomic status ( Table 1) . Most (59%) had NYHA class III or IV heart failure, the most severe classes of heart failure. Functional status at baseline as measured by the SF-12 physical and mental component scores and costs in the 3 months before randomization did not differ statistically significantly between groups. 
QALYs during the Intervention
Patients in the nurse-managed group maintained better physical functioning throughout the 12-month intervention than did patients who received usual care ( Figure  1) . Mental health did not differ statistically significantly by group. Each group had 22 deaths. Loss to follow-up was considerable in both groups, resulting in the need by month 12 to impute 35 and 41 SF-12 scores for nursemanaged and usual care patients, respectively. Translating the SF-12 scores into quality-of-life scores yielded higher quality of life in every period in the nurse-managed group. The difference in the area under these curves represents the increment in QALYs, and that difference was 0.0497 QALY per person for the HUI3 and 0.0430 QALY per person for the EQ-5D. Other translations of the SF-12 into QALYs (8 -10) yielded similar results, which are available from the authors.
Incremental Costs
Intervention costs totaled $2177 per patient. Nurse time ($1506 per patient) and physician and other investigator time ($232 per patient) were the largest cost components.
No cost categories statistically significantly differed between groups during the intervention, except for outpatient procedures, which were more costly in the nursemanaged group ( Table 2) . Lower costs per person for hospitalizations in the nurse-managed group were partially offset by higher costs for outpatient procedures and laboratory services and home care costs. Higher nursing home costs among nurse-managed patients were attributable largely to 2 patients who entered a nursing home within the first 3 months of the study. Higher physician home visit costs were due mainly to 1 nurse-managed patient who used home care extensively.
ICER
The 12-month incremental cost per QALY gainedthe ICER-was $17 543 for the estimate of quality of life based on translation of the SF-12 to the EQ-5D and $15 169 for translation to HUI-3 ( Table 3) . Adjustment for the small, statistically insignificant differences in quality of life between groups at baseline increased these estimates to $21 470 and $19 691, respectively. From the perspective of a payer like Medicare, the incremental net cost over 12 months of implementing this program was $158 per patient enrolled and $3673 and $3176 per QALY for EQ-5D-derived and HUI-3-derived quality of life, respectively ( Table 3) . Figure 2 (top) shows 500 bootstrapped replicates of incremental costs and incremental QALYs with a diagonal line representing all points with an ICER of $100 000 per QALY. The corresponding cost-effectiveness acceptability curve (bottom) suggests 64% and 77% probabilities that nurse-led management is cost-effective, at $50 000 per QALY and $100 000 per QALY, respectively. Figure 3 shows similar plots by NYHA class, with probabilities of cost-effectiveness at $100 000 per QALY of 76%, 97%, 21%, and 52% for patients with baseline NYHA classes I through IV, respectively.
Sensitivity Analyses
Limiting the sample only to patients who completed all survey rounds before they died or during 12 months suggested that the intervention improved quality of life and saved costs ( Table 4) . Limiting the sample to only observed responses resulted in an ICER of $18 599 per QALY (Table 4) , and replacing missing observations with patient-specific mean resulted in an ICER of $27 992 per QALY. Using national prices to calculate costs yielded ICER estimates of $15 556 and $13 460 per QALY gained, where the QALYs were measured by the EQ-5D and HUI3 methods, respectively ( Table 4) .
DISCUSSION
A nurse-led disease management program for patients with heart failure improved quality of life at an expected cost to society of less than $25 000 per QALY gained. The intervention costs of $2177 per patient were more than offset by reduced hospital costs ($2378 per patient), but higher costs for outpatient procedures, medications, and home health care prevented the intervention from being cost-saving over the 12-month study.
At less than $25 000 per QALY, nurse-led disease management for heart failure lies within the range usually considered a reasonable cost to gain 1 year of healthy life. Among studies from 1976 to 1996 that met an expert panel's criteria for creditable cost-effectiveness analysis, the median cost per QALY gained, translated to 2001 U.S. dollars, was $21 967 for health education and counseling interventions and $15 771 for interventions related to the circulatory system (23) . The lowest estimate of society's willingness to pay for 1 QALY from an analysis of the value-of-life literature was $28 811 (translated to 2001 U.S. dollars) (24) .
To our knowledge, this is the first cost-effectiveness analysis for nurse management of heart failure to include all recommended categories of cost. An English-language MEDLINE search (25 May 2008) found 6 U.S. RCTs of nurse management for heart failure that presented costs. One that reported all costs except patient time found that statistically significantly lower hospital costs in the nurse group were offset by higher intervention and caregiver costs, resulting in statistically insignificant total cost differences (25). Two studies that limited their cost analyses to inpatient care reported lower inpatient charges through 12 months or lower diagnosis-related group payments through 24 months among intervention patients (26, 27). Two studies that excluded the cost of the intervention or other cost categories found no cost difference among treatment groups (28, 29) .
A recent study conducted in San Antonio that took a health care system perspective reported no difference in direct medical costs and an ICER of $95 721 per QALY (2003 U.S. dollars) for patients with systolic dysfunction and $67 784 per QALY for patients with NYHA class III or IV symptoms (30) . These latter results contrast starkly with our study, which found better evidence of costeffectiveness for patients with NYHA class I and II heart failure. As Figure 3 shows, for patients with NYHA class I heart failure there was little evidence that the intervention improved QALYs; bootstrapped replicates of incremental costs and QALYs were scattered on either side of the vertical line for zero difference in QALYs. However, most points were below the zero-cost line, which suggests that the intervention reduced costs for patients with NYHA class I heart failure. This is reflected in the high but downward-sloping acceptability curve for patients with NYHA class I heart failure (Figure 3, bottom) . The height of the curve at $0 per QALY shows that if society were unwilling to incur any additional costs to improve quality of lifethat is, were we interested only in reducing costs-then nurse management for patients with NYHA class I heart ICER ϭ incremental cost-effectiveness ratio.
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Cost-Effectiveness of Nurse Management for Heart Failure failure is more likely to be acceptable, because 80% of the replicates suggest cost savings. The curve slopes downward because as society values interventions that improve QALYs more, the apparent ineffectiveness of the intervention for patients with NYHA class I heart failure reduces the likelihood that it is cost-effective. In contrast, patients with class II heart failure at baseline generally showed both higher QALYs and lower costs from the intervention and a high probability of cost-effectiveness for any maximum acceptable value of costs per QALY. Patients with class III or IV heart failure showed improved QALY but also had higher costs. The cost-effectiveness acceptability curves suggest relatively low probability that the intervention was cost-effective for these patients.
Our findings contrast with those of the San Antonio study because patient functioning in that study decreased in both treatment groups (31), whereas physical functioning in our study was maintained in the nurse-managed group over the 12-month intervention. As Figure 1 shows, the intervention yielded higher quality of life by forestalling the decline in physical functioning. This was especially true for patients with NYHA class II heart failure, resulting in a higher likelihood of cost-effectiveness for these patients. The intervention in the San Antonio study affected primarily survival among patients with systolic dysfunction and class III or IV heart failure. Dissimilar interventions and study populations may have contributed to these disparate results. The San Antonio study sample was 72% white, and 30% had diastolic dysfunction compared with our sample, which was 15% white and had only systolic heart failure. The nurse-led intervention in the former study was purely telephonic, whereas that in our study required an initial face-to-face patient meeting.
Our study has several limitations. We did not project costs and quality of life past the end of the 12-month intervention. Data from the main trial suggested that patients' SF-12 scores deteriorated after 12 months-when the nurses stopped working with the patients (6) . If the intervention has no durable effects on quality of life or costs, then the figures we present are reasonable estimates of the long-run cost effectiveness of a 12-month intervention, although we do not know the implications of continuing the intervention.
We conducted the trial in an ethnically diverse, innercity neighborhood, and these results may not be generalizeable to other settings. Nevertheless, because heart failure is a major cause of death and disability in these communities (3, 32, 33) , our findings are valuable and relevant to a large group of vulnerable patients with heart failure. Finally, the sizeable number of survey nonresponses required that we impute a large number of cost items and quality of life, although the sensitivity analyses suggest that the approach we took yielded reasonable results.
Given their established relationships with patients, hospital-based providers may be the most effective entity to administer a nurse management program. Financial considerations for providers, however, may inhibit the adoption of such a program, even one that is likely to improve health-related outcomes and is cost-effective from a societal perspective. Under mainstream U.S. payment arrangements that do not pay for disease management, a hospitalbased program would add the costs of the nurse managers to hospital expenses and would also reduce hospital revenues through avoided heart failure-related hospitalizations. Whether this is a net gain or loss to a hospital depends on several factors that are difficult to quantify, including the margin that a hospital earns on the avoided hospitalizations, but clearly payer reimbursement would encourage greater use of nurse management by hospitalbased providers.
Although cost-effective at less than $5000 per QALY gained, our nurse management intervention is unlikely to be cost-saving for the Medicare program if it covered all patients with heart failure. To our knowledge, no experimental evidence of nurse management for heart failure justifies an expectation of cost saving from a societal or any other perspective. The 12-month intervention would have cost Medicare $158 per patient, an estimate with reasonably good generalizability to similar communities given our trial's broad inclusion criteria and recruitment of patients from ambulatory settings. These findings match the results of Medicare's ongoing demonstration project, which randomly assigned patients with heart failure, diabetes, or coronary artery disease to disease management and found no evidence that the nurse management interventions were cost-saving or cost-neutral (34) . The appropriate question for policymakers, however, is not about costs in isolation, but whether the likely health benefits to be gained are worth the costs to be invested. Further research is clearly needed to understand which types of nurse management interventions and which types of patients with heart failure result in programs that provide good value for the money.
At less than $25 000 per QALY saved, this nurse-led disease management program was reasonably cost-effective over 12 months, especially for patients with earlier stages of heart failure. Wider adoption of such programs may be a sensible approach to reducing the burden of heart failure in ethnically diverse, urban communities. 
